About Fizzy-related protein homolog
Fizzy-related protein homolog (FZR1) is a protein
from Homo sapiens identified by UniProt accession
Q9UM11, 496 residues long.
MolForge cross-references it against 0 known binders and
72 disease associations.
Target properties
| Protein name | Fizzy-related protein homolog |
| UniProt accession | Q9UM11 |
| Gene | FZR1 |
| Organism | Homo sapiens |
| Length | 496 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (72)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- undetermined early-onset epileptic encephalopathy · score 0.37
- genetic disorder · score 0.34
- Global developmental delay · score 0.29
- lysosomal storage disease · score 0.28
- Red cell distribution width · score 0.23
- low grade glioma · score 0.23
- clear cell renal carcinoma · score 0.18
- endometrial cancer · score 0.14
- Seizure · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UM11-F1 | alphafold | PREDICTED | 82.36 | — |
Amino-acid sequence (496 residues)
MDQDYERRLL RQIVIQNENT MPRVTEMRRT LTPASSPVSS PSKHGDRFIP SRAGANWSVN FHRINENEKS PSQNRKAKDA TSDNGKDGLA YSALLKNELL GAGIEKVQDP QTEDRRLQPS TPEKKGLFTY SLSTKRSSPD DGNDVSPYSL SPVSNKSQKL LRSPRKPTRK ISKIPFKVLD APELQDDFYL NLVDWSSLNV LSVGLGTCVY LWSACTSQVT RLCDLSVEGD SVTSVGWSER GNLVAVGTHK GFVQIWDAAA GKKLSMLEGH TARVGALAWN AEQLSSGSRD RMILQRDIRT PPLQSERRLQ GHRQEVCGLK WSTDHQLLAS GGNDNKLLVW NHSSLSPVQQ YTEHLAAVKA IAWSPHQHGL LASGGGTADR CIRFWNTLTG QPLQCIDTGS QVCNLAWSKH ANELVSTHGY SQNQILVWKY PSLTQVAKLT GHSYRVLYLA MSPDGEAIVT GAGDETLRFW NVFSKTRSTK VKWESVSVLN LFTRIR
Explore Fizzy-related protein homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets